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Abstract: Collagen Tissue Disease–associated Interstitial Lung Fibrosis (CTD-ILDs) and Bronchiolitis
Obliterans Syndrome (BOS) represent severe lung fibrogenic disorders, characterized by
fibro-proliferation with uncontrolled extracellular matrix deposition. Hyaluronic acid (HA) plays a
key role in fibrosis with its specific receptor, CD44, overexpressed by CTD-ILD and BOS cells. The
aim is to use HA-liposomes to develop an inhalatory treatment for these diseases. Liposomes with
HA of two molecular weights were prepared and characterized. Targeting efficiency was assessed
toward CTD-ILD and BOS cells by flow cytometry and confocal microscopy and immune modulation
by RT-PCR and ELISA techniques. HA-liposomes were internalized by CTD-ILD and BOS cells
expressing CD44, and this effect increased with higher HA MW. In THP-1 cells, HA-liposomes
decreased pro-inflammatory cytokines IL-1β, IL-12, and anti-fibrotic VEGF transcripts but increased
TGF-β mRNA. However, upon analyzing TGF-β release from healthy donors-derived monocytes, we
found liposomes did not alter the release of active pro-fibrotic cytokine. All liposomes induced mild
activation of neutrophils regardless of the presence of HA. HA liposomes could be also applied for
lung fibrotic diseases, being endowed with low pro-inflammatory activity, and results confirmed that
higher MW HA are associated to an increased targeting efficiency for CD44 expressing LFs-derived
from BOS and CTD-ILD patients.
Keywords: liposomes; Bronchiolitis Obliterans Syndrome; lung fibrosis; hyaluronic acid; immune cells
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1. Introduction
Collagen Tissue Disease–associated Interstitial Lung Fibrosis (CTD-ILDs) and Bronchiolitis
Obliterans Syndrome (BOS) represent two severe lung fibrogenic disorders involving, respectively,
the lung interstitium and small airways, which share several pathogenic mechanisms and a poor
long term outcome [1,2]. Common pathogenic steps include injury of airway epithelium due to
immune-inflammatory insults, followed by a trigger of alveolar and bronchiolar epithelial cells
transition towards myofibroblasts (epithelial mesenchymal transition, EMT) and a fibro-proliferative
phase with uncontrolled extracellular matrix (ECM) deposition. Among ECM components (collagens,
elastin, fibronectin, elastic fibers) [3], hyaluronic acid (HA) is the main one that characterizes fibrotic
processes [4]. HA is a non-sulfated glycosaminoglycan synthesized by three transmembrane HA
synthase (HAS1, HAS2, and HAS3) and binds specific protein partners: CD44 and the receptor for
hyaluronan-mediated motility (RHAMM). Regarding CD44, the interaction with HA exerts a wide
range of different physiological and pathological cell regulatory functions. In fibrosis, it has been
demonstrated that HA enhances aberrant fibrotic cells motility through the binding with CD44 and
RHAMM [5]. Moreover, Midgley et al. showed that EMT TGF-β-dependent of alveolar and bronchiolar
epithelial cells was dependent upon HA/CD44/EGFR cascade [6].
We have recently demonstrated that primary lung fibroblasts (LFs) isolated from bronchoalveolar
lavage (BAL) of CTD-ILD or BOS affected patients expressed a high rate of HA receptor CD44, and that
this receptor represented a relevant and useful molecule with which to develop targeted nanovehicles [7].
In particular, we synthesized gold nanoparticles functionalized with a specific monoclonal antibody
for CD44 in order to study their cytotoxicity onto LFs. We demonstrated that targeted nanovehicles
efficiently decreased the viability of LFs in vitro, but in vivo analyses showed a trend of accumulation
into alveolar macrophages after long-term inhalatory treatment of rodents [8]. As such, we decided to
move toward more biocompatible nanocarriers (liposomes) decorated with a physiological targeting
moiety. HA-functionalized nanocarriers are preferentially applied in cancer treatment [9–12], but given
the important role of HA-CD44 interaction in tissues fibrosis progression, several research groups
started to exploit HA-nanoparticles as drug delivery systems for liver fibrosis [13]. Regarding lung
fibrosis, Chiesa et al. have already tried to exploit the properties of HA in drug delivery using chitosan
nanoparticles, but theirs is the only research paper in this field [14].
Consequently, we planned to exploit the possibility of using HA-liposomes as vehicles to set the
basis for an inhalatory treatment of CTD-ILD and BOS. To this aim, we decided to use two different
low MW HA (4800 and 14,800 Da) for the preparation of liposomes, in order to explore, for the first
time, the effect of HA MW on the targeting efficiency on lung fibrotic cells and inflammatory effectors.
In particular, herein we describe the preparation, characterization, and biological properties evaluation
of three different liposome preparations (LIP, LIP-HA4800, and LIP-HA14800) toward primary LFs
derived from BOS or CTD-ILD affected patients and in the modulation of pro-inflammatory/fibrotic
responses. Moreover, as our future perspective is the administration of HA-liposomes by an inhalatory
route, we additionally assessed cell uptake on other lung cell types: human bronchial epithelial cell line
(16-HBE), human alveolar basal epithelial cell line (A549), and mucus-producing bronchial epithelial
cell line (Calu-3).
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2. Results
2.1. Liposomes Formulation, and Characterization
LIP, LIP-HA4800, and LIP-HA14800, either blank and fluorescently labeled, were prepared
by hydration of the lipid film followed by extrusion through polycarbonate filters to obtain
homogenous small unilamellar vesicles. LIP-HA4800 and LIP-HA14800 were prepared by adding the
HA4800-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) or HA14800-DPPE conjugates
during the hydration phase of lipid film: in this way, the phospholipidic chain was incorporated into the
liposome membrane, while the HA was exposed toward the aqueous phase. For plain liposomes (LIP),
l-α phosphatidyl-dl-glycerol sodium salt (PG) was used instead of HA-DPPE conjugates. Liposomes
dimensions ranged from about 200 nm to 250 nm and the particle size of the HA-liposomes tended to
increase with the increase of polymer MW, as previously reported [15]. The polydispersity index (PDI)
was low for all the formulations (<0.18), and the zeta potential value was negative, for HA-liposomes
the negative charge increased as the polymer MW increased due to the carboxylic negative residues of
HA on the surface (Table S1).
2.2. Cells Internalization of Liposomes
In order to study the interactions of the three liposomal preparations with LFs derived from
CTD-ILD and BOS, we firstly analyzed liposomes internalization by confocal microscopy, comparing
results with A549 (CD44high), Calu-3 (CD44mild) 16-HBE (CD44neg) cell lines. Figure 1 shows that
only HA-liposomes at both MW were internalized by BOS- (Figure 1a–c) and CTD-ILD- (Figure 1d–f)
LF cells after 4 h of incubation. More internalization was observed upon incubating HA-liposomes
with A549 with respect to LFs (Figure 1g–i), even if they had the same cell surface expression of
CD44 (Table S2). As expected, we observed no significant interaction of LIP-HA at both MWs with
16-HBE (Figure S1a–c) and Calu-3 (Figure S1d–f), due to their poor expression of CD44 (Table S2).
However, Figure S1f shows that only LIP-HA14800 were able to interact with Calu-3, although less
than CD44high cells.
To quantify the internalization of LIP, LIP-HA4800 and LIP-HA14800 by flow cytometry we
decided to study only A549 and BOS- and CTD-ILD-LFs cells, since they demonstrated more significant
results by confocal microscopy. As expected, we observed a higher interaction of LIP-HA with A549
(Figure 2C) rather than BOS- (Figure 2A) and CTD-ILD-LFs (Figure 2B), confirming confocal images
(Figure 1). Moreover, thanks to this technique we understood that in all three cell lines the grade of
liposomes cells uptake significantly increases with higher HA MW.
2.3. ECM Pericellular Coating
Knowing that BOS- and CTD-ILD-LFs produce a large amount of ECM, we wanted to further
study whether the presence of ECM could be the cause of a different behavior of HA-liposomes
interaction with these cells in comparison to A549 cells. Therefore, we co-cultured LFs or A549 with
1 × 108 erythrocytes and confirmed that LFs release a pericellular ECM (Figure S2A) [4], as opposed
to A549 (Figure S2B). Moreover, through incubating LFs with fluorescently labeled HA, which had
been previously prepared in our laboratory, it was possible to observe a labeled-HA deposition as
extracellular filamentous forms in LFs (Figure S3C) and not in A549 cells (Figure S2D), thus confirming
the tendency of HA to interact with ECM produced by LFs in culture.
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Figure 1. Confocal images of fluorescently labeled LIP (a,d,g), LIP-HA4800 (b,e,h) and LIP-HA14800 
(c,f,i) and incubated with BOS-LFs (a–c), CTD-ILD-LFs (d–f) and A549 (g–i). Nuclei of cells = light 
blue (DAPI); liposomes = green signals. Scale bar = 50 μm. 
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2.4. Liposomes Mucus Diffusion
As our final goal is to administer liposomes through an inhalatory route, we wanted to study the
interaction of three liposomal preparations with mucus layer coating respiratory epithelium. With this
aim, we assessed mucus penetration on a 23-day culture of Calu-3 cells cultivated in air-liquid interface
(ALI) configuration. The homogenous production of a mucus layer in these experimental conditions
was previously assessed by alcian blue staining (Figure S3). With the aid of confocal microscopy, we
were able to detect unfunctionalized liposomes in all sections made by z-stack (Figure 3A). On the
contrary, HA decorated liposomes were found at deeper levels (only at the lower slice of z-stack: see
Figure 3B,C) after the same incubation time. LIP-HA14800 were also able to reach cells and to interact
with some of them (Figure 3C), confirming the results obtained in Figure S1f.
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Figure 2. Flow cytometry analyses of fluorescently labeled LIP, LIP-HA4800, and LIP-HA14800 
incubated with BOS-LFs (A), CTD-ILD-LFs (B), and A549 (C). Histograms represent mean of mean 
fluorescence intensity of liposomes ± standard deviation. *, p < 0.05 vs. CTR; **, p < 0.01 vs. CTR; ***, p 
< 0.001 vs. CTR. 
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Figure 2. Flow cytometry analyses of fluorescently labeled LIP, LIP-HA4800, and LIP-HA14800
incubated with BOS-LFs (A), CTD-ILD-LFs (B), and A549 (C). Histograms represent mean of mean
fluorescence intensity of liposomes ± standard deviation. *, p < 0.05 vs. CTR; **, p < 0.01 vs. CTR;
***, p < 0.001 vs. CTR.
2.5. THP-1 Cell Uptake
Efficient cellular uptake is a major requirement for the therapeutic efficacy of liposomes targeting,
but in BOS and CTD-ILD, context is also important in order to consider the effect of different liposomal
formulations on immune system modulation. Considering the important role of macrophages in lung
fibrosis progression and the high expression of CD44 on their surface [16,17], we analyzed whether
liposomes would be internalized by the human monocytic leukemia cell line (THP-1 cells) differentiated
toward macrophages lineage with PMA. First, we confirmed the expression of CD44 on THP-1 by flow
cytometry. Table S2 shows that both undifferentiated and differentiated THP-1 highly expressed CD44,
and differentiation with PMA increased CD44 expression as reported in the literature [18]. Next, to
analyze cellular uptake, we treated cells with fluorescently labeled LIP, LIP-HA4800, and LIP-HA14800
for the indicated times. We observed a rapid internalization of all liposomes, reaching plateau after 2 h,
(approximately 85%, Figure 4A). In addition, the cellular uptake efficiency seems not to be dependent
on the MW of HA. We investigated whether the observed liposomes uptake was mediated by cell
surface CD44 receptor, and thus we pre-incubated differentiated THP-1 with a saturable amount of
free high MW HA (51,000 Da) and subsequently with different liposomal formulations. These studies
evidenced that the blockage of the receptor did not reduce the cell lar uptake of liposomes, suggesting
that in THP-1 cells the uptake is not CD44-depe dent (Figure 4B), but rather is due to the phagocytic
activity of this cell line.
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2.6. Effect of Liposomes on Cytokines Expression
Finally, we analyzed whether the different formulations of liposomes may modulate the activation
of THP-1 cells. Specifically, we focused our attention on the determination of the transcript levels
of well-known cytokines expressed by pro-inflammatory macrophages (M1) (IL-1β and IL-12) and
cytokines correlated to the M2 phenotype (TGF-β, VEGF) involved in anti-inflammatory, pro-fibrotic,
and pro-angiogenetic effects by quantitative real-time PCR (qRT-P R) [19]. In our study, we
found preliminarily that the exposure of differentiated human THP-1 cells to LIP, LIP-HA4800,
and LIP-HA14800 significantly downregulated the transcript levels of the pro-inflammatory cytokines
IL-1β and IL-12 with respect to the control cells (Figure 5A,B), while all formulations were able to
induce the increase transcript levels of TGF-β cytokine (Figure 5C), with the highest effect occurring
after incubation with LIP-HA14800. The pro-angiogenetic VEGF-A transcript level was significantly
downregulated compared to control by all treatments (Figure 5D).
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Figure 5. Analysis of transcript levels of IL-1β (A), IL-12 (B), TGF-β1 (C), and VEGF-A (D) in
differentiated THP-1 cells. Quantitative real-time PCR (qPCR) of mRNAs of THP-1 cells treated for
1 h with LIP, LIP-HA4800, and LIP-HA14800. mRNA values are expressed as fold increase over
control values after normalization to the GAPDH gene expression and are the means ± SEM of three
independent experiments. *, p < 0.05, **, p < 0.01, ***, p < 0.001 vs. CTR.
2.7. Effect of Liposomes on Monocytes and Neutrophils Derived From Blood of Healthy Donors
Even if the increase of TGF-β transcript in THP-1 differentiated cells induced by liposomes could
be seen as anti-inflammatory activity, this cytokine plays a key role in fibrotic processes [19,20]. Hence,
we decided to further study the effect of liposomes on monocytes isolated from the blood of healthy
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donors, analyzing the release of TGF-β and not the expression of mRNA, in order to have more
reliable results on a physiologic cell line model. Figure 6A shows that treatment with all formulations
did not significantly alter the release of pro-fibrotic cytokine from monocytes, compared to positive
control treatment. Moreover, we assessed the ability of three preparations to modulate the release of a
pro-inflammatory cytokine strongly related to neutrophilic inflammation, IL-8, from monocytes. LIP
and LIP-HA4800 led to an increase of IL-8 release, rather than LIP-HA14800 (Figure 6B).
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Figure 6. Liposomes biological effects on TGF-β (A) and IL-8 (B) release by monocytes isolated from
peripheral blood. Analyses of CD11b surface expressio on neutrophils by flow cytometer. All analyses
were conducted after treating cells with LIP, LIP-HA4800 and LIP-HA14800 after 24 h f r monocytes
(A,B) and 4 h for neutrophils (C). LPS treatment was used as control. Data are represented as histograms
of mean ± standard deviation. *, p < 0.05 vs. CTR; ***, p < 0.001 vs. CTR.
Since it has been demonstrated that both BOS and CTD-ILD start with an insult of lung epithelium
by activated neutrophils, we decided to additionally analyze if liposomes were able to modulate this
population. With this intent, we incubated neutrophils isolated from blood with LIP, LIP-HA4800,
and LIP-HA14800, assessing the surface expression of CD11b, a surface marker of activation and
degranulation [21]. Figure 6B shows that all formulations increased the surface expression of CD11b
on neutrophils, but less than LPS ositiv co trol. Furthermore, since this effect was observed in
lipos mes dec rated or not with HA, we can presume that the result w s n t due to the presence of
HA but rather o the activation of neutroph ls induced by liposom phagocyt sis.
3. Discussion
HA is a physiologic glycoprotein used as moiety to functionalize nanocarriers to target cancer cells
overexpressing CD44, one of the principal HA receptors. Since it has been reported that primary fibrotic
cells express high rates of CD44 [7,9,22], researchers have started to exploit the same functionalization
moiety to develop a targeted nano-based therapy for fibrosis. Regarding pulmonary fibrosis, only
one paper has been published thus far describing the advantage of using HA conjugated onto
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nanoparticles [14]. With the work herein, we wanted to provide the basis for using HA as ligand
to develop targeted nano-therapy against cells causing two lung fibrotic disorders—CTD-ILD and
BOS. These severe diseases are associated to poor survival and as yet, treatment strategies are scarce,
inadequate and associated to a significant systemic toxicity.
We have already studied and demonstrated that the use of drug-loaded gold nanoparticles
functionalized with anti-CD44 antibody could be useful in inhibiting LFs proliferation inducing
apoptosis [7]. However, in vivo experiments, aerosolizing nanoparticles to healthy mice, demonstrated
that gold nanocarriers tended to accumulate inside lungs, mainly in alveolar macrophages. This
observation raised the issue of a possible significant toxicity associated to long term inhalatory
treatment. For this reason, we shifted our attention to more biocompatible nanovehicles, liposomes,
due to their numerous reported advantages [23–26]. Our future goal is to deliver liposomes through
the inhalation route in order to enhance therapeutic efficiency and avoid first-pass metabolism, and it
has been demonstrated that this kind of nanoparticles are efficient in localizing the action of inhaled
drugs in the lung. Moreover, they are already being used in clinical trials [26].
In the present study, we started to assess liposomes decorated with HA at two different MW.
The choice of HA size is a crucial aspect due to the different activity of HA based on its MW [15]. In
the literature, all MW of HA have been employed, from high MW to oligomers; herein, we decided
to decorate liposomes with low MW HA (4800 and 14,800 Da). We were able to efficiently decorate
liposome surfaces with both MW HA (mean particles size increased in correlation to MW of HA) with
a good polydispersity index (<0.7) (Table S1) [27]. After liposomes characterization, we analyzed the
targeting efficiency of LIP-HA4800 and LIP-HA14800 on LFs CTD-ILD and BOS-derived comparing
results with liposomes without HA decoration (LIP). We thus demonstrated that HA is essential for
internalization of liposomes. Moreover, the internalization is greater with HA14800 with respect to
HA4800. This result is reasonable because HA is characterized by a repeated nature, so higher MW
have more binding sites for CD44 [28,29]. However, we observed less internalization of LIP-HA with
LFs as compared to A549 (positive control cell lines) (Figures 1 and 2), even if they expressed the same
quantity of surface receptor CD44 (Table S2). We subsequently analyzed the presence of pericellular
coating, observing that only LFs derived from CTD-ILD and BOS showed this phenomenon due to
their ability to produce ECM as fibrotic cells (Figure S3).
As our aim is the administration of HA-liposomes through the inhalation route, we assessed if the
presence of HA onto liposomes could modulate the diffusion of nanovehicles into the mucus layer
coating respiratory epithelium. For this purpose, we used an airway epithelium model (Calu-3) [30]
in ALI configuration to allow the production of mucus. Following treatment with LIP, LIP-HA4800
and LIP-HA14800, we demonstrated that HA14800 increased the diffusion efficiency of liposomes
in contrast to HA4800 (Figure 3). To the best of our knowledge, in the literature there are studies
analyzing mucus penetrating ability of nanovehicles, correlating this activity to surface charge and to
MW of polyethylene glycol (PEG) coating [31–33]. Very recently a research group modified lipoplexes
(LX) for siRNA delivery to the lung with PEG and HA and demonstrated that non-PEGylated HA-LX
diffused comparably to PEGylated LX, in contrast to non-modified LX, which remained entrapped in
the mucus [33]. In this paper we observed the same result using liposomes without PEG modification:
mucus penetration increased in the presence of HA.
Having assessed the behavior of liposome formulations with cells and mucus, we moved on to
analyze whether nanovehicles were able to modulate immune cells activity, since BOS and CTD-ILD
are due to a significant dysregulated local inflammatory response. Firstly, we used THP-1, a monocitic
cell line, after differentiation induced by PMA. Analyses of THP-1 mRNA transcripts after treatment
with LIP, LIP-HA4800, and LIP-HA14800 demonstrated that all treatments decreased the expression of
IL-1β and IL-12, two relevant pro-inflammatory cytokines [34]. Since we are studying two lung fibrotic
disorders, we decided to also analyze the VEGF and TGF-β mRNA levels due to their involvement
in the pathogenesis of ILD [35]. All liposomal formulations led to a decrease of mRNA of VEGF
(Figure 5D), while TGF-β expression increased after treatments, in particular with LIP-HA14800
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(Figure 5C). This suggests that liposomes, in particular those decorated with HA14800, enhanced
THP-1 PMA-induced toward an M2 phenotype, indirectly increasing the expression of pro-fibrogenic
TGF-β. Although the THP-1 cell line is an established model for monocytic behavior and exerts many
functions similar to blood monocytes, there exists some evidence indicating a significant divergence
between the differentiation pattern of PMA stimulated THP-1 and peripheral monocytes [36]. Thus,
we decided to assess liposomes modulation in the release of pro-inflammatory cytokine, IL-8 (strongly
related to neutrophilic inflammation) and TGF-β in monocytes isolated from peripheral blood obtained
from healthy donors. We demonstrated that only LIP-HA14800 did not alter the release of IL-8, but
none of our liposomes were able to significantly alter TGF-β release (Figure 6A). The discrepancy
regarding Figures 5C and 6A can be explained by the neoplastic and poorly differentiated nature of
THP-1 cells that need to be maximally induced by PMA treatment, altering the response to liposomes.
Finally, the neutrophils activation status was assessed by evaluating the CD11b surface expression
level after liposomes treatment, since neutrophils are involved in early pathogenesis of CTD-ILD and
BOS. Flow cytometry allowed us to determine that all formulations were capable of inducing a mild
increase of CD11b expression level regardless of the presence of HA, even if significantly less than LPS
positive control (Figure 6B). We assume that this result was due to the phagocytic nature of neutrophils.
In conclusion, we can infer that HA decoration of liposomes might be useful in the targeted
treatment of lung fibrotic disorders, and, in addition, in our experimental models, we confirmed
that a higher HA MW increases the CD44 targeting efficiency without a significant associated
pro-inflammatory activity.
4. Materials and Methods
4.1. Materials and Instruments
Sodium hyaluronate of MW 4800 (HA4800) and 14,800 (HA14800) Da were purchased from Lifecore
Biomedical (Chaska, MN, USA). All the phospholipids were provided by Avanti Polar-Lipids distributed
by Sigma-Aldrich S.r.l. (Milan, Italy). Cholesterol, all the other chemicals, RPMI, amphotericin-B, and
alcian blue were obtained from Sigma-Aldrich S.r.l. Fluorescein-5-(and-6)-sulfonic acid trisodium salt
was purchased from Invitrogen, Life Technologies (Monza, Italy) Conjugates between HA and DPPE
(HA-DPPE) were prepared using the method described in Arpicco et al. [14]. Dulbecco’s modified
Eagle medium (DMEM), fetal calf serum (FCS), penicillin/streptomycin (P/S) solution, l-glutamine and
phosphate buffer saline (PBS) were all purchased by Euroclone (Milan, Italy).
4.2. Preparation of Liposomes
Liposomes were prepared by thin lipid film hydration and extrusion method. Briefly, a
chloroform solution of the lipid components 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
cholesterol (Chol), and PG (70:30:3 molar ratios) was evaporated and the resulting lipid film
was dried under vacuum overnight. Lipid films were hydrated with HEPES [4-(2-hydroxyethyl)
piperazine-1-ethanesulforic acid] buffer (pH 7.4), and the suspension was vortexed for 10 min and bath
sonicated. The formulations were then sequentially extruded (Extruder, Lipex, Vancouver, BC, Canada)
through a 400, and then a 200 nm polycarbonate membrane (Costar, Corning Incorporated, NY, USA) at a
set temperature of 5 ◦C above the phase transition temperature of the lipid mixture. Fluorescently labeled
liposomes were prepared as described above and a 10 mM solution of fluorescein-5-(and-6)-sulfonic
acid trisodium salt in HEPES buffer was used during hydration. Liposomes were then purified through
chromatography on Sepharose CL-4B columns, eluting with HEPES buffer at room temperature.
To prepare HA-liposomes, the same method of preparation was used and the lipid film was
hydrated using a solution of the different HA-DPPE conjugates (three molar ratio) in HEPES buffer.
Liposomes were stored at 4 ◦C.
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4.3. Liposomes Characterization
The mean particle size and the PDI of liposomes were determined at 25 ◦C by quasi-elastic light
scattering (QELS) using a nanosizer (Nanosizer Nano Z, Malvern Inst., Malvern, UK). The selected
angle was 173◦ and the measurement was made after dilution of the liposome suspension in MilliQ®
water. Each measure was performed in triplicate. The particle surface charge of liposomes was
investigated by zeta potential measurements at 25 ◦C applying the Smoluchowski equation and using
the Nanosizer Nano Z. Measurements were carried out in triplicate. Phospholipid phosphorous was
assessed in each liposome preparation by phosphate assay after destruction with perchloric acid [37].
4.4. Cell Lines
A549 (CD44high), Calu-3 (CD44mid) 16-HBE (CD44neg) cell lines (all purchased from ATCC®,
Manassas, VA, USA) were cultivated in high glucose DMEM supplemented with 10% FCS, 100 U mL–1
P/S solution and 100 U mL–1 l-glutamine.
In order to allow the formation of a mucus layer, Calu-3 were cultured in ALI configuration:
1 × 106 cells were seeded on the apical compartment of six-well transwell (0.4 µm pore size, Corning
Costar, Lowell, MA, USA). The apical medium was removed after 24 h to allow the establishment of
air-interface. Every two days, the medium on the apical side was eliminated and fresh medium was
added only in the basal compartment until a complete layer of mucus was produced (day 23).
LFs were isolated from Bronchoalveolar Lavage (BAL) of patients affected by BOS and CTD-ILD
obtained following standard recommendations [7]. 6 × 106 cells were seeded in the same medium of
cultivation. Single foci of LFs formed between 1–3 weeks were isolated and cultivated.
A549, Calu-3, 16-HBE and LFs were characterized for CD44 expression (using anti-CD44-FITC
antibody, Beckman Coulter, Brea, CA, USA) by flow cytometer (Navios, Beckman Coulter, Brea,
CA, USA).
Human monocytic leukemia cell line (THP-1 cells, purchased by ATCC®, Manassas, VA, USA)
was maintained in RPMI medium supplemented with 10% FCS, 100 U mL–1 P/S and 25 µg mL–1
amphotericin-B. For all experiments with THP-1, 7 × 105 cells were seeded in 35 mm petri dishes
(Corning Costar, Lowell, MA, USA) and differentiated into macrophages-like phenotype with phorbol
12-myristate 13-acetate (PMA, 50 nM) for 48 h. After 24 h of incubation with fresh medium, THP-1
cells were then treated with LIP, LIP-HA4800, and LIP-HA14800.
4.5. Histological Staining for Mucus Production
Alcian blue was used to stain mucus secretion by Calu-3. At days 3, 7, 14, 18, and 23, Calu-3 cells
were washed with PBS, fixed with 4% paraformaldehyde and stained with alcian blue (1% w/v alcian
blue in 3% v/v acetic acid/water at pH 2.5). Subsequently, the filter membranes were cut and mounted
on glass slides using glycerol and sealed. The slides were imaged using an Olympus BX41 microscope
(Olympus, Tokyo, Japan).
4.6. Confocal Microscopy
A549, Calu-3, 16-HBE and LFs were seeded on 35 mm glass bottom petri dish (Corning Costar,
Lowell, MA, USA) at a density of 1.5 × 104 cells. After 24 h, cells were incubated with LIP, LIP-HA4800
and LIP-HA14800 fluorescently labeled for 4 h at 37 ◦C. Next, cells were washed with PBS, fixed with
4% paraformaldehyde and DAPI solution was added to label the nuclei of cells.
To analyze the mucus penetration of different formulations of liposomes, we cultivated Calu-3 in
ALI configuration to produce mucus. We then treated cells with LIP, LIP-HA4800, and LIP-HA14800
fluorescently labeled for 24 h at 37 ◦C. Cells were washed with PBS, fixed with 4% paraformaldehyde
and DAPI solution was added to label the nuclei of cells.
Cells were observed by confocal laser microscopy Fluoview FV10i (Olympus, Tokyo, Japan).
Regarding liposomes mucus penetration, cells were analyzed with a z-stack of 5 µm/slice.
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4.7. Flow Cytometry for Liposomes Utake
A549, BOS-, and CTD-ILD-LFs were seeded on 12-well plates at a density of 2.5 × 104 cells. After
24 h, cells were incubated with LIP, LIP-HA4800, and LIP-HA14800 fluorescently labeled for 4 h at
37 ◦C. Cells were then washed with PBS, harvested in cytometer tubes and analyzed by flow cytometer
(Navios, Beckman Coulter, Brea, CA, USA) to quantify fluorescent signal.
Differentiated THP-1 cells seeded in 6-well culture plates (7 × 105 cells), were exposed for 1 h
to fluorescently labeled LIP, LIP-HA4800 and LIP-HA14800. Cells were also pre-incubated with
100×molar excess of free high MW HA (51,000 Da) for 1 h. Following medium removal, cells were
washed twice with PBS, collected by using a cell scraper and finally re-suspended in 1 mL of PBS.
Next, the intracellular uptake of liposomes was analyzed using a BD FACSCanto™ system (Becton
Dickinson, Franklin Lakes, NJ, USA). Detection of fluorescent liposomes was carried out using FL-1
channel acquiring 10,000 events per samples, using Kaluza software and CellQuest software for Navios
and Becton-Dickinson flow cytometers, respectively. Cells incubated in the absence of liposomes were
used as control.
4.8. qRT-PCR
RNA extraction, complementary DNA synthesis, and qRT-PCR reactions were performed as
previously described (Cannito et al. 2015). Human IL-1β, IL-12, TGF-β1, and VEGF-A mRNA
levels were measured using the SYBR® green method as described [38]. The amplification mix
was prepared using Roche LightCycler FastStart DNA MasterPLUS SYBR Green I kit following
manufacturer’s instructions and real-time PCR was performed using LightCycler instrument
(Bio-Rad CFX Connect Thermocycler, Hercules, CA, USA). Oligonucleotide sequence of primers
used for qRT-PCR were: sense, 5′-TGAAAGCTCTCCACCTCCAG-3′, ′reverse 5′-CACGCAGGAC
AGGTACAGAT-3′ (for human IL-1β); sense, 5′-AAGGAGGCGAGGTTCTAAGC-3′, reverse,
5′-AAGAGCCTCTGCTGCTTTTG-3′ (for human IL-12); sense, 5′-GGGACTATCCACCTG
CAAGA-3′, reverse, 5′-CCTCCTTGGCGTAGTAGTCG-3′ (for human TGF-β1); sense,
5′-CCCACTGAGGAGTCCAACAT-3′, reverse, 5′-TTTCTTGCGCTTTCGTTTTT-3′ (for human
VEGF-A). Gliceraldehyde-3-phosphate dehydrogenase (GAPDH, sense: 5′-TGGTATTCGGGA
AGGACTCATGAC-3′, reverse: 5′-ATGCCAGTGAGCTTCCCGTTCAGC-3′) was used as internal
reference and co-amplified with target samples using identical qRT-PCR conditions. Samples were run
in triplicate and mRNA expression was generated for each sample. Specificity of the amplified PCR
products was determined by melting curve analysis and confirmed by agarose gel electrophoresis.
4.9. Neutrophils and Monocytes Blood Isolation
Leucocytes were obtained from healthy blood donors collected at the Transfusion Center of
San Matteo Hospital and monocytes were isolated by gradient centrifugation with Lympholyte®
(Cedarlane, Ontario, ON, Canada) in 50 mL conical tube and centrifuged for 30 min at 500 rcf without
brake. Regarding monocytes, the peripheral blood mononuclear cell (PBMC) layer was carefully
transferred into a new 50 mL conical tube and diluted with physiologic solution, centrifuged for
10 min decreasing the rcf of centrifugation to 200 rcf. Concerning neutrophils isolation, after cells
blood separation with Lympholyte®, only the neutrophils layer was collected and washed with a
physiologic solution and centrifuged at 400 rcf for 10 min. Cell pellet was lysed with VersaLyse™
(Beckman Coulter, Brea Beckman Coulte, Brea, CA, USA) for 20 min at room temperature to eliminate
erythrocytes. Physiologic solution was added, and cells were centrifuged at 400 rcf for 10 min. This
step was repeated until the erythrocytes were completely abolished.
4.10. Neutrophils Activation
1 × 106 neutrophils derived from healthy donor blood were treated with LIP, LIP-HA4800, and
LIP-HA14800 for 1 h at 37 ◦C. 2 µg mL−1 LPS was used as positive control. Afterwards, cells were
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labeled with antibodies against CD45-APC and CD11b-PE (Beckman Coulter, Brea, CA, USA) and
analyzed with flow cytometry acquiring 10,000 events per sample, using Kaluza software (version 1.0,
Beckman Coulter, Brea, CA, USA).
4.11. IL-8 and TGF-β Release From Monocytes
IL-8 and TGF-β production by monocytes was evaluated by ELISA technique. 2.5 × 105
monocytes isolated from blood of healthy donors were incubated for 24 h with LIP, LIP-HA4800
and LIP-HA14800. Positive control cells were incubated with 1 µg mL−1 LPS. After incubations,
surnatants were collected and centrifuged at 300 rcf to eliminate cells and debris. Next, surnatants
were treated following the instructions of the manufacturers of Quantikine ELISA Human IL-8/CXCL8
Immunoassay kit (R&D system, Minneapolis, MN, USA) and Human TGF-β ELISA kit (Sigma-Aldrich,
Milan, Italy). Obtained absorbance values were interpolated with the standard curve and expressed as
mean ± standard deviation.
4.12. Statistical Analyses
Statistical differences between untreated cells and cells treated with liposomes were evaluated
using one-way ANOVA analysis followed by Dunnett post hoc test for multiple comparison. All
analyses were carried out with a GraphPad Prism 5.0 statistical program (GraphPad software, San Diego,
CA, USA). A value p < 0.05 was considered statistically significant.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/24/18/3291/s1,
Table S1: Characteristics of liposomal formulations, Table S2: Mean Fluorescence Intensity (MFI) of CD44
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Pericellular coating and HA-fluorescent deposition, Figure S3: Alcian blue staining.
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